Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Shanghai Argo Biopharmaceutical Co. Ltd. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is distributed across 2 distinct art units, indicating that the company's innovations are being examined under different technical classifications. The prosecution involves a matching number of distinct examiners, which means each pending matter is being handled by a separate individual at the USPTO.
The busiest examiner for this portfolio is PERSONS, JENNA L, who is responsible for 1 pending office action. Since there are multiple pending actions in total, the workload is split between the assigned examiners. Practitioners should note that no single examiner holds a majority of the current workload, requiring a tailored approach for each distinct art unit involved in the prosecution.
The presence of 2 distinct art units within the Biotechnology & Pharmaceuticals sector suggests that the company's patent strategy covers multiple biological or pharmaceutical specialties. With the pending office actions to address, the legal team must coordinate responses across these separate administrative divisions. Monitoring the specific tendencies of PERSONS, JENNA L and the other examiner will be essential for achieving successful outcomes.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PERSONS, JENNA L | 1 | 50.8% | +61.7% |
| BABIC, CHRISTOPHER M | 1 | 60.6% | +23.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18554692 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ANGIOPOIETIN-LIKE 3 (ANGPTL3) PROTEIN | BABIC, CHRISTOPHER M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18730467 | COMPOSITION AND METHOD FOR INHIBITING EXPRESSION OF PROTEIN LPA(APO(A)) | PERSONS, JENNA L | — |
| 18554692 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ANGIOPOIETIN-LIKE 3 (ANGPTL3) PROTEIN | BABIC, CHRISTOPHER M | — |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18730467 | COMPOSITION AND METHOD FOR INHIBITING EXPRESSION OF PROTEIN LPA(APO(A)) | PERSONS, JENNA L | 1637 | §103§112DP | Non-Final OA | — | Pending | Jul 19, 2024 |
| 18554692 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ANGIOPOIETIN-LIKE 3 (ANGPTL3) PROTEIN | BABIC, CHRISTOPHER M | 1633 | §103§112 | Non-Final OA | — | Pending | Oct 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShanghai Argo Biopharmaceutical Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Jenna L Persons has the most, with 1 of Shanghai Argo Biopharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
